CClinicalTrials.gg
RecruitingNCT06774651Updated Jan 14, 2025

Comparison of Femto LDV Z8 Corneal Lenticule Extraction for Advanced Refractive Correction (CLEAR) and Visumax Small Incision Lenticule Extraction (SMILE)

An observational study in Myopia, sponsored by Singapore Eye Research Institute. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-14.

Sponsored by Singapore Eye Research Institute · Observational

From the registry’s dates

  • Primary completion was expected by Oct 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 7 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
65
Ages
21 Years to 50 Years
Sex
All
01

Study summary

This observational study aims to compare two laser corrective procedures for treating myopia and myopic astigmatism: a novel refractive technique, the CLEAR procedure, and the established SMILE procedure. Participants will be randomized to undergo CLEAR in one eye and SMILE in the other. The investigators will evaluate and compare the two procedures based on the following aspects: refractive predictability (how accurate the vision correction is) by measuring the proportion of eyes close to the target prescription after surgery, clinical dry eye outcomes, changes in tear proteins, and corneal nerve changes at 1, 3, 6, and 12 months after both surgeries. Metabolomic features of the removed corneal tissue and how precisely the laser is centered during surgery will also be examined. Our hypothesis is that CLEAR provides equally good vision results as SMILE, and explore any extra benefits of CLEAR.

Read the detailed description

Surgical correction for refractive errors may be performed by a number of procedures. Laser correction involves refractive procedures such as laser assisted in-situ keratomileusis (LASIK), small incision lenticule extraction (SMILE), flap based refractive lenticule extraction (femtosecond lenticule extraction and pseudo-SMILE), surface ablation techniques like photorefractive keratectomy or laser epithelial keratomileusis, while lens-based corrections involve the use of phakic intra-ocular lenses.

SMILE (Visumax) is a flapless refractive procedure which was introduced in 2011 for the treatment of myopia and myopic astigmatism. In this procedure a stromal lenticule is extracted through a small incision (2.0 to 5.0 mm). It involves docking, femtosecond laser application, lenticule dissection from the surrounding stroma, and extraction. Studies have suggested that using a SMILE technique resulted in better ocular surface stability and biomechanical strength when compared with LASIK. SMILE has a steep learning curve. The most common complication encountered during the initial learning curve, is difficult lenticule dissection and extraction with an incidence of up to 16%. Other intraoperative complications include suction loss, an opaque bubble layer, and tearing of the lenticule.

Corneal Lenticule Extraction for Advanced Refractive Correction (CLEAR) by FEMTO LDV Z8 (Ziemer) is a novel technique of flapless refractive surgery which uses low energy femtosecond laser. It creates highly focused laser pulses achieving photodisruption in the low nanojoules range (\<100 nJ). Decreased stromal gas generation and accurate laser focus are the advantages of this low energy concept. The advantages of CLEAR treatment are possibility of recentering the treatment area after having performed the docking, which is not possible with the VisuMax Laser System, multiple corneal incisions for easy removal of the lenticule for the beginners, trusted vacuum with minimal suction losses. Previous study concluded that the mean preoperative sphere, cylinder, and spherical equivalents were -3.05 (D), 0.50 D, and -3.30 D respectively and 1 month after CLEAR the sphere, cylinder and spherical equivalents were 0.05 D, 0.3 D and 0.12 D respectively.

As the investigators do not expect to see a great improvement to the results from the already established SMILE procedure, the investigators aim to demonstrate that CLEAR is just as good in terms of visual outcomes. However, the investigators aim to show that CLEAR has additional benefits, on top of the equal or comparative visual outcomes.

Currently there are no publications comparing the refractive predictability, higher order aberrations, changes in tear neuromediators, tear proteomics, keratocytes and nerve regeneration, corneal lenticule metabolomics, intraoperative laser centration comparing CLEAR and SMILE, hence this study will be unique in the fact that the paired eye approach will act as an internal patient control to assess the objective and subjective outcomes in patients following both these procedures.

02

Conditions studied

  • Myopia

Browse trials for

Keywords

  • CLEAR
  • FEMTO LDV Z8
  • SMILE
  • Visumax
  • Myopia
03

In context

Myopia

984 studies on the registry are indexed under Myopia; 210 are open to participants now.

This study's planned enrollment of 65 is below the median of 150 across 173 observational studies indexed under Myopia.

Browse Myopia studies →

Lead sponsor

Singapore Eye Research Institute is the lead sponsor of 26 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

A total of 65 subjects (130 eyes- 65 CLEAR eyes and 65 SMILE eyes) will be recruited in the study from refractive clinic at Singapore National Eye Centre.

Inclusion criteria

  • >/= 21 years of age and \</= 50 years of age.
  • Cycloplegic spherical equivalent of >-1.00D
  • Refractive cylinder -2.00 D or less; anisometropia \<1.00D
  • Best spectacle corrected visual acuity (BSCVA) of 6/12 or better in BOTH eyes.
  • Spherical or cylindrical error has progressed at -0.50D or less per year from date of baseline measurement.
  • Contact lens wearers must have removed contact lenses at least two (2) weeks before the baseline measurement.
  • No evidence of irregular astigmatism on corneal topography.
  • Available to attend post-operative examinations for a 12-month period.

Exclusion criteria

Exclusion Criteria:

  • Progressive or unstable myopia and/or astigmatism.
  • Clinical or corneal topographic evidence of keratoconus.
  • Patients who want bilateral SMILE procedure
  • Patients who want extracted corneal lenticule to be stored for future refractive surgery.
  • Residual, recurrent or active ocular disease such as uveitis, severe dry eyes, severe allergic eye disease, glaucoma, visually significant cataract and retinal disease.
  • Previous corneal surgery or trauma within the corneal treatment zone.
  • Corneal vascularisation within 1mm of the corneal treatment zone.
  • Taking systemic medications likely to affect wound healing, such as corticosteroids and antimetabolites.
  • Systemically immunocompromised.
  • Systemic disease likely to affect wound healing, such as diabetes, connective tissue disease and severe atopy.
  • Pregnant or nursing.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
65 participants (estimated)
Patient registry
No

Groups and cohorts

  • 1. CLEAR surgery eyes

    Eyes that have undergone CLEAR procedures.

    Procedure: Procedure: Corneal lenticule extraction for advanced refractive correction (CLEAR)

  • 2. SMILE surgery eyes

    Eyes that have undergone SMILE procedures.

    Procedure: Procedure: Small Incision Lenticule Extraction (SMILE)

Interventions

  • ProcedureProcedure: Corneal lenticule extraction for advanced refractive correction (CLEAR)

    Routinely conducted procedure using FEMTO LDV Z8 laser system for correction of Myopia.

  • ProcedureProcedure: Small Incision Lenticule Extraction (SMILE)

    Routinely conducted procedure using VisuMax laser system for correction of Myopia.

    Also known as: SMILE

06

What researchers measure

Primary outcomes

  1. Rate of refractive predictability

    Refractive predictability is defined as the proportion number of eyes achieving a postoperative spherical equivalent (SE) within ±1.0 D of the intended target. Uncorrected visual acuity (UCVA), refraction, and best corrected visual acuity (BCVA) will be recorded.

    Time frame: 1 year

Secondary outcomes

  1. Level of higher order aberrations

    Higher-order aberrations are small optical irregularities of the eye that cannot be corrected with regular spectacles and most contact lenses. HOAs are responsible for an array of visual symptoms such as difficulty seeing at night, glare, halos, blurring, starburst patterns, or double vision.

    Time frame: 1 year

  2. Tear Break Up Time (TBUT)

    TBUT will be measured by determining the time interval between a complete blink and the first appearance of a dry spot on the corneal surface, indicating tear film stability.

    Time frame: 1 year

  3. Concentration of tear neuromediators assessed by enzyme-linked immunosorbent assay

    Tear fluid samples will be collected by the strips from Schirmer's I test. The neuromediators concentration in all tear samples will be analyzed using the enzyme-linked immunosorbent assay

    Time frame: 1 year

  4. Corneal sensitivity measurements assessed by Cochet-Bonnet esthesiometer

    Corneal sensitivity measurements assess the responsiveness of the cornea to external stimuli using a contact esthesiometer (Cochet-Bonnet), evaluating the functional status of corneal nerves.

    Time frame: 1 year

  5. NEI score

    Corneal fluorescein staining

    Time frame: 1 year

  6. Oxford grading

    Corneal and conjunctival staining

    Time frame: 1 year

  7. Ocular Surface Disease Index (OSDI) questionnaire to measure eye symptoms and the impact of quality of life

    The Ocular Surface Disease Index questionnaire is a 12-item questionnaire that used to assess the eye symptoms and and their impact on vision-related quality of life. The total Ocular Surface Disease Index score (ranging between 0 and 100) is used for evaluation, with higher scores representing greater severity of symptoms.

    Time frame: 1 year

  8. Extent of keratocytes activation

    In vivo confocal microscopy will be used to capture images of keratocytes at the surgical interface, with different hyperreflective states indicating varying degrees of keratocyte activation.

    Time frame: 1 year

  9. Laser centration accuracy measured by the offset between the optical zone center and corneal vertex

    Functional optical zone will be calculated using the software on Pentacam refractive power maps. Centration accuracy will be evaluated by the linear distance between the functional optical zone centroid and the corneal vertex.

    Time frame: 1 year

  10. Metabolites profiles of corneal lenticule

    Metabolomic analysis technique will be used to identify and quantify small molecules in the corneal lenticule, helping to understand metabolic pathways and physiological processes related to surgeries.

    Time frame: 1 year

  11. Amount of tear production measured by Schirmer's I test

    Schirmer's I test is a diagnostic method used to measure tear production by placing a standard 5 mm wide Test Strips inside the lower lid margin and assessing the amount of tear absorbed over 5 minutes.

    Time frame: 1 year

  12. Abundance of tear proteins assessed by quantitative proteomic analysis

    Tear fluid samples will be collected by the strips from Schirmer's I test. Quantitative proteomic analysis technique will be used to measure and compare the abundance of proteins across different samples, providing insights into protein expression, functions, and molecular interactions.

    Time frame: 1 year

  13. Ocular Pain Assessment Survey (OPAS) questionnaire to measure eye pain

    The Ocular Pain Assessment Survey (OPAS) is a 27-item questionnaire to evaluate the eye pain from 6 dimensions, including pain intensity for the last 24h, pain intensity for the last 2 weeks, non-eye pain intensity, quality of life, aggravating factors, associated factors and symptom relief. Each question was scored on a scale of 0-10, with higher score representing worse pain.

    Time frame: 1 year

  14. Extend of corneal nerve impairment

    IVCM will be used to capture corneal nerve images before and after surgeries. The extend of corneal nerve damage following surgery will be quantified using seven nerve parameters by a specialized image analysis software (ACCMetrics software).

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06774651
Lead sponsor
Singapore Eye Research Institute
Responsible party
Sponsor
First posted
Jan 14, 2025
Start date
Mar 1, 2023
Primary completion
Oct 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jan 14, 2025

Study contacts

Jodhbir S Mehta, MD, FRCS
Contact
jodhbir.s.mehta@singhealth.com.sg
6322 7478
Jodhbir S Mehta, MD, FRCS
principal investigator · Singapore National Eye Centre

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion